Literature DB >> 3298620

Effects of low-dose cyclosporine prophylaxis in nonobese diabetic mice.

B Formby, N Miller, R Garret, C M Peterson.   

Abstract

Among female nonobese diabetic mice, ketotic insulin-dependent diabetes mellitus (IDDM) develops spontaneously in 80% between 12 and 26 weeks of age. This condition resembles human type I diabetes. IDDM developed in 0 of 11 (0%) mice prophylactically treated with 10 mg of cyclosporine A (CyA) per kg s.c. every 4th day from 8 to 26 weeks of age; 8 of 10 (80%) of sex- and age-matched controls developed IDDM; 2 of 8 (25%) followed up to 5 months beyond the time of drug administration developed IDDM. The distribution of specific radioactivity ([3H]CyA) was used to calculate the concentrations of CyA in serum, blood cells and various organs. Serum values of CyA produced by radioimmunoassay were higher than those estimated by the [3H]CyA method. Pancreata of CyA-treated mice were histologically normal. Pancreata of control mice showed lymphocytic infiltration of the islets of Langerhans. Neither hepatotoxicity nor nephrotoxicity assessed by biochemical and histological data was detectable in CyA-treated mice. The insulin secretory capacity of trypan blue viable functional pancreatic islets isolated post-treatment; was significantly lower in controls than in CyA-treated mice; islet content of insulin was not statistically different between controls and CyA-treated mice. We conclude that low nontoxic doses of CyA abrogate completely the development of diabetes in the female nonobese diabetic mouse and abolish lymphocytic infiltration of the islets of Langerhans against which there is autoimmunity. The effect of CyA persists well past the duration of therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3298620

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice.

Authors:  W L Baeder; J Sredy; S N Sehgal; J Y Chang; L M Adams
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

2.  Autologous CD4 T-cell responses to ectopic class II major histocompatibility complex antigen-expressing single-cell islet cells: an in vitro insight into the pathogenesis of lymphocytic insulitis in nonobese diabetic mice.

Authors:  B Formby; N Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

3.  Reversal of beta-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus.

Authors:  E Strandell; D L Eizirik; S Sandler
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

4.  Cyclosporine pharmacokinetics and effect in the type I diabetic rat model.

Authors:  L J Brunner; L V Iyer; K Vadiei; W V Weaver; D R Luke
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

Review 5.  Lessons from the NOD mouse for the pathogenesis and immunotherapy of human type 1 (insulin-dependent) diabetes mellitus.

Authors:  E F Lampeter; A Signore; E A Gale; P Pozzilli
Journal:  Diabetologia       Date:  1989-10       Impact factor: 10.122

6.  Protective role of gammadelta T cells in spontaneous ocular inflammation.

Authors:  Rebecca L O'Brien; Molly A Taylor; Jacqueline Hartley; Tanja Nuhsbaum; Steve Dugan; Kevin Lahmers; M Kemal Aydintug; J M Wands; Christina L Roark; Willi K Born
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-17       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.